4-(2-Ethoxy-2-oxoethyl)sulfanylnaphthalene-1,8-dicarboxylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4-(2-Ethoxy-2-oxoethyl)sulfanylnaphthalene-1,8-dicarboxylic acid
• 化学式: C₁₆H₁₄O₆S
• 分子量: 334.3
• InChiKey: GRSZLZQSCUBIMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  126
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same
  申请人：——

  公开号：US20030185793A1

  公开（公告）日：2003-10-02

  The invention relates to transport molecule binding ligand compounds which comprise a therapeutically and/or diagnostically active substance and a carrier molecule-affine substance with a high association constant to the carrier molecule. The invention also relates to medicaments containing these ligand compounds and to diagnostic kits.

  这项发明涉及与载体分子结合的配体化合物，其包括具有治疗和/或诊断活性物质以及与载体分子具有高结合常数的载体分子亲和物质。该发明还涉及含有这些配体化合物的药物和诊断试剂盒。
• THERAPEUTISCHE UND DIAGNOSTISCHE LIGANDENSYSTEME MIT TRANSPORTMOLEKÜLBINDENDEN EIGENSCHAFTEN UND DIESE ENTHALTENDE ARZNEIMITTEL
  申请人：KTB Tumorforschungsgesellschaft mbH

  公开号：EP1272223B1

  公开（公告）日：2006-05-31
• US7902144B2
  申请人：——

  公开号：US7902144B2

  公开（公告）日：2011-03-08
• [EN] SMALL MOLECULE ANTAGONISTS OF PF4 CONTAINING ULTRA LARGE COMPLEXES<br/>[FR] ANTAGONISTES À PETITES MOLÉCULES DE PF4 CONTENANT DES COMPLEXES ULTRA-LARGES
  申请人：TRUSTEES OF THE UNIVERSITY OF PENSYLVANIA

  公开号：WO2013142328A1

  公开（公告）日：2013-09-26

  Methods for preventing formation of or disrupting PF4 tetramers are provided. The compounds useful in such methods bind to a PF4 tetramer, dimer, or monomer. The compounds are also useful for preventing formation of or disrupting ultra-large complexes containing a PF4 tetramer and a glycosaminoglycan, and thus have utility toward preventing or treating medical conditions related to the formation of PF4 tetramers, such as HITT and atherosclerosis and toward correcting a platelet imbalance, preventing a decrease in platelet production and increasing high density lipoproteins in a subject. Also provided are compositions and kits containing these compounds and optional medications which cause the formation of PF4 tetramers, and/or medications which disrupt PF4 tetramers. [Formula I]